Log in to save to my catalogue

Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment

Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_896f5a83aa354941b6e45e2c416ab912

Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment

About this item

Full title

Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment

Publisher

Melbourne: Wiley Publishing Asia Pty Ltd

Journal title

JGH open, 2022-05, Vol.6 (5), p.301-308

Language

English

Formats

Publication information

Publisher

Melbourne: Wiley Publishing Asia Pty Ltd

More information

Scope and Contents

Contents

Background and Aim
Conversion surgery (CS), which aims to cure after systematic therapy, is only scarcely reported in the field of hepatocellular carcinoma (HCC). However, advancements in systemic therapy for HCC are expected to increase the candidates eligible for CS because of the higher response rate. The aim of this study was to clarify the...

Alternative Titles

Full title

Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_896f5a83aa354941b6e45e2c416ab912

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_896f5a83aa354941b6e45e2c416ab912

Other Identifiers

ISSN

2397-9070

E-ISSN

2397-9070

DOI

10.1002/jgh3.12735

How to access this item